GEN Exclusives

More »

GEN News Highlights

More »
Jan 14, 2008

Artes and Minapharm Sign Deal Related to Hansenula Platform

  • Artes Biotechnology and Rhein Minapharm Biogenetics, a subsidiary of Minapharm, entered into a strategic collaboration to develop three therapeutic proteins. Artes will apply its Hansenula technology and know-how to the generation of production cell lines, analytical assay development, and lab-scale fermentation.

    Additionally, Artes granted Minapharm a commercial license option to apply its technologies to the manufacturing and marketing of these therapeutic proteins. Artes also will be responsible for the 100 L scale production of a Minapharm protein based on an existing process using E. coli. Minapharm will carry out the pertinent process R&D, production, and commercialization of the therapeutic proteins.

    The yeast strain Hansenula polymorpha is often an alternative to E. coli for producing therapeutic proteins or technical enzymes, explains Michael Piontek, founder and managing director of Artes. A number of products derived from Hansenula are already marketed worldwide, such as hepatitis B vaccine, insulin, interferon alpha 2a, and feed and food enzymes, he adds, noting that several others are in clinical trials.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »